Spliceostatin A

Spliceostatin A is a potent splicing inhibitor. Spliceostatin A (SSA) causes cell cycle arrest at G1 and G2/M phases. Spliceostatin A treatment inhibits mitotic clonal expansion and adipogenesis. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation. Spliceostatin A binds to the SF3B subcomplex of the U2 small nuclear ribonucleoprotein particle (snRNP), limits U1 snRNP availability in splicing, resulting in premature cleavage and polyadenylation of MALAT1, a nuclear lncRNA, as well as protein-coding mRNAs. Therefore, truncated transcripts are exported into the cytoplasm and translated, resulting in aberrant protein products.

Product information

CAS Number: 391611-36-2

Molecular Weight: 521.64

Formula: C28H43NO8

Chemical Name: (2Z, 4S)-4-(Acetyloxy)-N-[(2R, 3R, 5S, 6S)-tetrahydro-6-[(2E, 4E)-5-[(3R, 4R, 5R, 7S)-4-hydroxy-7-methoxy-7-methyl-1, 6-dioxaspiro[2.5]oct-5-yl]-3-methyl-2, 4-pentadien-1-yl]-2, 5-dimethyl-2H-pyran-3-yl]-2-pentenamide

Smiles: C[C@]1(C[C@@]2(CO2)[C@H](O)[C@@H](/C=C/C(/C)=C/C[C@@H]2O[C@H](C)[C@@H](C[C@@H]2C)NC(=O)/C=C\[C@H](C)OC(C)=O)O1)OC

InChiKey: XKSGIJNRMWHQIQ-CGPJBNNXSA-N

InChi: InChI=1S/C28H43NO8/c1-17(9-12-24-26(32)28(16-34-28)15-27(6,33-7)37-24)8-11-23-18(2)14-22(20(4)36-23)29-25(31)13-10-19(3)35-21(5)30/h8-10,12-13,18-20,22-24,26,32H,11,14-16H2,1-7H3,(H,29,31)/b12-9+,13-10-,17-8+/t18-,19-,20+,22+,23-,24+,26+,27-,28+/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Kaida D, Shida K. Spliceostatin A stabilizes CDKN1B mRNA through the 3' UTR. Biochem Biophys Res Commun. 2022 Mar 29;608:39-44. doi: 10.1016/j.bbrc.2022.03.085. Epub ahead of print. PMID: 35381427.
2. Kikuchi K, Kaida D. CCNE1 and E2F1 Partially Suppress G1 Phase Arrest Caused by Spliceostatin A Treatment. Int J Mol Sci. 2021 Oct 27;22(21):11623. doi: 10.3390/ijms222111623. PMID: 34769053; PMCID: PMC8584075.
3. Yoshimoto R, Chhipi-Shrestha JK, Schneider-Poetsch T, Furuno M, Burroughs AM, Noma S, Suzuki H, Hayashizaki Y, Mayeda A, Nakagawa S, Kaida D, Iwasaki S, Yoshida M. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation. Cell Chem Biol. 2021 Sep 16;28(9):1356-1365.e4. doi: 10.1016/j.chembiol.2021.03.002. Epub 2021 Mar 29. PMID: 33784500.

Products are for research use only. Not for human use.